Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

Kobra Shiasi,1 Farbod Talebian,2 Seyyed Peyman Khamechi,2 Hassan Nikoueinejad,3,* Mojtaba Sehat,4 Zohreh Azarbad,4 and Behzad Einollahi3

1Department of Pediatrics, Kashan University of Medical Sciences, Kashan, IR Iran
2Student Research Committee, Kashan University of Medical Sciences, Kashan, IR Iran
3Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4Department of Community Medicine, Kashan University of Medical Sciences, Kashan, IR Iran

*Corresponding author: Hassan Nikoueinejad, Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-3615550021; +98-9131615530, Fax: +98-2188067114, E-mail: hnikuinejadi@yahoo.com

Received 2017 May 02; Revised 2017 June 24; Accepted 2017 August 19.

Abstract

Background: The main indicator of long-term glycemic control in type 1 diabetes and its complications is glycosylated hemoglobin (HbA1c). Considering that there are little studies on the correlation of YKL-40 with HbA1c in type 1 diabetes, we evaluated such correlation to suggest YKL-40 as both diagnostic and prognostic marker of type 1 diabetes poor control and nephropathy.

Methods: 49 patients of type 1 diabetes not suffering from any diabetic complications during recent 5 years and 43 sex- and age-matched healthy controls participated in the study. Taking fasting blood and urine samples, we measured CBC, serum levels of YKL-40, HbA1c, creatinine, lipids, and urinary concentration of albumin and creatinine using standard laboratory methods.

Results: Serum level of YKL-40 was significantly higher in type 1 diabetes compared to controls (P < 0.001). There was no significant correlation between such levels and HbA1c (P = 0.99) in type 1 diabetic patients. There was a strong positive correlation between YKL-40 and duration of the disease (P < 0.001). We found no significant correlation between serum level of YKL-40 and other factors including urine/albumin creatinine ratio (UACR), blood pressure, lipid profile, and serum and urine creatinine.

Conclusions: Although there was a significant increase in serum level of YKL-40 in type 1 diabetic patients, it did not show any correlation with both metabolic and nephropathic states of diabetes.

Keywords: Type 1 Diabetes (T1D), YKL-40, HbA1c, Diabetic Nephropathy

1. Background

Diabetes mellitus (DM) imposes a group of common metabolic irregularities that share the phenotype of hyperglycemia (1) associated with microvascular complications (2) including atherosclerosis (3, 4) and coronary artery disease (3). The relationship between metabolic control and development of chronic adverse complications in type 1 diabetes (T1D) has always been a great concern over the years, and nowadays the main indicator of long-term glycemic control in T1D and its complications is glycosylated hemoglobin (HbA1c) (5). Although elevated baseline, mean or updated mean of HbA1c levels have been correlated with diabetic complications (reviewed in (6)), actually several studies have introduced some biomarkers of inflammation and endothelial dysfunction in T1D with or without microvascular complications or diabetic nephropathy (7-9).

YKL-40, also called human cartilage glycoprotein-39 or chitinase 3-like-1 (CHI3L1) (10), is a member of mammalian chitinase-like proteins binding to lectin without chitinase activity (11). YKL-40 is secreted by different human cells including inflammatory cells such as neutrophils (12) and macrophages (13). A substantial body of evidence indicates that YKL-40, as an inflammatory marker in different pathologies (14-17), participates in diabetes as well as its complications including endothelial dysfunction (13), atherosclerosis (18), cardiovascular disease (19, 20), and albuminuria (19).

Considering that there are little studies on the correlation of YKL-40 with HbA1c and diabetic nephropathy in T1D (19), we evaluated such correlation to suggest YKL-40 as both diagnostic and prognostic marker of T1D metabolic control as well as of diabetic nephropathy.
2. Methods

Study population: 49 patients with type 1 diabetes not suffering from any diabetic complications during recent 5 years and 43 sex- and age-matched healthy controls participated in the study. The healthy controls with no family history of diabetes were selected from voluntary blood donors of local blood donation organization. The diagnosis of T1D was based on the American diabetes Association's criteria. Any subject with a history of internal diseases other than diabetes and its complications and use of anti-hypertensive or lipid-lowering drugs as well as smokers was excluded from the study. The protocol was approved by the local committee of ethics. The study was designed in accordance with the Helsinki declaration. Written informed consent was obtained from all participants older than 16 years or their parents/guardians in the case of younger ones.

Sampling protocol and measurements: Blood and urine samples were taken at 08:00-10:00 in the morning after 12 hours overnight fasting. CBC, serum levels of YKL-40, HbA1c, blood biochemical markers including creatinine, lipid profile, and urinary concentration of albumin and creatinine were measured using standard laboratory methods. Urine albumin and urine/serum creatinine were evaluated through enzymatic immunassay and Jaffe’ methods, respectively. Albumin/creatinine ratio was quantified in 3 urine samples. A commercial, sandwich type ELISA kit (Quidel, San Diego, CA, USA) was used to measure serum levels of YKL-40 according to kit’s instructions.

Statistical analysis: Variables with normal distribution are presented as mean ± SD. The groups were compared using an unpaired Student’s t test or Welch test. Differences in proportions were tested by the χ²-test or Fisher’s exact test. Pearson’s univariate test was used to correlate between the variables. P < 0.05 was considered statistically significant. All analyses were performed using statistical software package SPSS (version 18; SPSS, Chicago, IL).

3. Results

Demographic, experimental, and clinical characteristics of participants are presented in Table 1. HbA1c and serum level of YKL-40 were significantly higher in T1D patients compared to control subjects (P < 0.001) (Figure 1). 83.7% (n = 41) of T1D patients showed a concentration of serum YKL-40 more than the 90% percentile of the healthy controls (42.68 µg/mL). Serum YKL-40 levels were also significantly higher in diabetics according to sex and age compared to those in sex- and age-matched non-diabetics (P < 0.001). There was no significant correlation between the serum levels of YKL-40 and HbA1c (P = 0.99) in T1D patients. Otherwise, it did show strong positive correlations only with duration of the disease (P < 0.001) (Table 2, Figure 2). In addition, we did not find any significant correlation between YKL-40 serum levels and UACR (as independent marker of diabetic nephropathy), blood pressure, lipid profile, and serum and urine creatinine (Table 2).

4. Discussion

In line with some other studies (19, 21), we found a higher YKL-40 serum level in the group of T1D patients. Such elevation has also been reported in pre-diabetic (13) as
As a role player of metabolic status (22, 23), it seems that YKL-40 may be a factor influencing HbA1c as a metabolic indicator of diabetes. Having investigated if there was a correlation between HbA1c and serum level of YKL-40, we could not find such correlation. Studying on the correlation of YKL-40 levels with HbA1c in type 2 diabetes, some researchers have found a significant correlation between plasma (24) as well as urine (25) levels of YKL-40 and HbA1c while some others (13, 22, 26, 27) have not found such correlation. In the case of T1D, other studies (20, 21) and ours did not find such correlation.

A significant correlation between YKL-40 plasma levels and age has been a matter of agreement (19, 20, 22, 23, 25, 26, 28-30) or disagreement (14, 31-34) (like ours) in different studies. Such pros (23, 24, 35) (like ours) and cons (13, 14, 19, 27) issues are also true in the case of the significant correlation of YKL-40 levels with HbA1c in type 2 diabetes, well as in type 2 diabetic patients (13, 20). Moreover, to our knowledge, we report, for the first time, an elevated YKL-40 concentration in a homogenously young population of type 1 diabetics concerning the duration of diabetes with a small standard deviation (73.22 ± 5.9 months) as well as no medical history of diabetic complications and any other diseases.

In agreement (22) and disagreement with some other studies (19, 21), we found no significant correlation be-

**Table 1.** Basic and Clinical Characteristics of the Patients and Control Group

| Variants                        | Healthy Controls (n = 43) | TID (n = 49) | P Value |
|---------------------------------|--------------------------|-------------|---------|
| Age, y                          |                          |             | 0.12    |
| Gender (male/female)            | 21/22                    | 22/27       | 0.7     |
| Duration of diabetes, mo        | -                        | 73.22 ± 5.9 | 0.001   |
| BMI, kg/m²                      | 21.02 ± 4.25             | 21.23 ± 4.6 | 0.826   |
| Systolic BP, mmHg               | 114.33 ± 9.08            | 112.73 ± 10.37 | 0.439 |
| Diastolic BP, mmHg              | 75.02 ± 8.96             | 71.53 ± 8.59 | 0.06    |
| HbA1c, %                        | 4.73 ± 0.73              | 7.34 ± 1.24 | -       |
| RBC, Million/µL                 | 5 ± 0.52                 | 5.18 ± 1.4  | 0.421   |
| Hemoglobin, g/dL                | 14.36 ± 1.36             | 15.63 ± 1.16 | 0.007  |
| Hematocrit, %                   | 43.32 ± 1.62             | 41.18 ± 3.09 | 0.003  |
| Total cholesterol, mg/dl        | 159.6 ± 25.2             | 169.3 ± 23.1 | 0.059  |
| Triglyceride, mg/dl             | 75.91 ± 27.76            | 77.73 ± 28.4 | 0.758  |
| HDL, mg/dL                      | 37.67 ± 6.27             | 40.61 ± 7.09 | 0.039  |
| VLDL, mg/dL                     | 15.86 ± 5.33             | 15.46 ± 5.87 | 0.555  |
| LDL, mg/dL                      | 106.26 ± 19.6            | 113.24 ± 17.43 | 0.074 |
| Creatinine, mg/dl               | 1.07 ± 0.2               | 0.87 ± 0.14 | < 0.001 |
| YKL-40 ng/mL                    |                          |             |         |
| Sex                             |                          |             |         |
| Male                            | 28.44 ± 2.37             | 10.54 ± 10.46 | < 0.001 |
| Female                          | 28.34 ± 1.92             | 107.53 ± 10.11 | < 0.001 |
| P Value                         | 0.97                     | 0.84        | -       |
| Age, y ≤ 12 (n)                 |                          | 27.03 ± 2.6 (10)  | 113.34 ± 9.20 (28) | < 0.001 |
| Age, y > 12 (n)                 |                          | 28.86 ± 1.82 (28) | 102.94 ± 1.67 (21) | < 0.001 |
| P Value                         | 0.6                      | 0.48        | -       |
| Total                           | 28.39 ± 9.84             | 108.48 ± 50.53 | < 0.001 |
| eGFR, ml/min/1.73 m²            | 87.1 ± 34.4              | 90.6 ± 27.8  | 0.64    |
| UACR, mg/g Cr                   | 3.95 ± 0.41              | 12.16 ± 1.53 | < 0.001 |
| Urine protein, mg/dl            | 2.01 ± 2.27              | 1.69 ± 1.52  | 0.538   |
| Urine creatinine, mg/dl         | 265.73 ± 158.60          | 136.58 ± 57.97 | < 0.001 |

**Table 2.** Correlation of Serum Levels of YKL-40 with Different Parameters in 2 Groups

| Variable                        | Control Group (P Value) | Diabetic Group (P Value) |
|---------------------------------|-------------------------|--------------------------|
| Agea                           | -0.050 (0.751)          | 0.046 (0.752)            |
| Duration of diabetesa          | -                       | 0.789 (< 0.001)          |
| BMId                           | -0.144 (0.359)          | 0.282 (0.04)             |
| Systolic BP, mmHg              | 0.094 (0.548)           | -0.279 (0.052)           |
| Diastolic BP, mmHg              | 0.374 (0.265)           | -0.04 (0.783)            |
| Hemoglobin, g/dla              | -0.076 (0.627)          | -0.018 (0.902)           |
| Hematocrit, %b                  | -0.15 (0.336)           | -0.032 (0.829)           |
| HbA1c, %b                      | 0.148 (0.344)           | 0.00 (0.995)             |
| Total cholesterol, mg/dl       | -0.067 (0.668)          | 0.049 (0.738)            |
| Triglyceride, mg/dle           | -0.027 (0.866)          | 0.182 (0.21)             |
| HDL, mg/dl                     | 0.012 (0.94)            | -0.12 (0.411)            |
| VLDL, mg/dl                    | -0.1 (0.524)            | 0.19 (0.191)             |
| LDL, mg/dl                     | 0.11 (0.484)            | 0.029 (0.841)            |
| Creatinine, mg/dl              | -0.366 (0.028)          | 0.04 (0.787)             |
| Urine Albumin, mg/dl           | -0.029 (0.855)          | -0.07 (0.628)            |
| Urine creatinine, mg/dl        | 0.008 (0.959)           | 0.11 (0.45)              |
| UACRa                          | -0.088 (0.575)          | -0.13 (0.168)            |

aNon-parametric.  
bParametric.
between YKL-40 and UACR in T1D patients. This inconsistency may be conceivable considering that our patients were young people suffering for about 6 years from diabetes. Such short duration may be insufficient to develop nephropathic complications.

The advantage of our study was that we used a relatively appropriate sample size and associated standard deviations that made a proper power to detect differences in subgroup analyses. Moreover, there were no essential biases affecting the comparability of the groups including large differences in age, duration of diabetes, and length of treatment. A few studies (19, 21) could show such uniformity of the patients.

We did not monitor the changes of YKL-40 serum levels through serial samples. This would be the main limitation of our cross-sectional study that suffers from the lack of longitudinal data.

Acknowledgments

This study was funded and supported by deputy of research, Kashan University of Medical Sciences (KAUMS), and grant No. 8934.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Wiener C, Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, et al. Harrison’s Principles of Internal Medicine Self-Assessment and Board Review 11th Edition. McGraw Hill Professional; 2012.
2. Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Balkau B, Buse JB, et al. Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):1369-79. doi: 10.1056/NEJM199309303291401. [PubMed: 8366622].
3. Kavey RE, Allada V, Daniels SR, Hayman LI, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. J Cardiovasc Nurs. 2007;22(3):248-53. doi: 10.1177/104738770730044X. [PubMed: 17549224].
4. Vigili de Kreutzgen S, Tiengo A, Avogaro A. Cerebrovascular disease in diabetes mellitus: the role of carotid intima-media thickness. Nutr Metab Cardiovasc Dis. 2009;19(9):667-73. doi: 10.1016/j.numecd.2009.03.014. [PubMed: 19509058].
5. Gerstl EM, Rahi W, Rosenbauer J, Grobe H, Hofer SE, Krause U, et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 47,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr. 2008;167(4):447-53. doi: 10.1007/s00431-007-0586-9. [PubMed: 17924412].
6. Lind M, Oden A, Fahlen M, Eliasson B. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes Metab Syndrome Clin Res Rev. 2008;2(4):282-93. doi: 10.1016/j.dsx.2008.04.006.
7. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005;108(2):343-59. doi: 10.1046/j.1365-2141.2005.02605.x. [PubMed: 16031329].
8. Schram MT, Choquette N, Schalkwijk CG, Fuller JH, Stehouwer CD. Endothelial Prognosticative Complexion Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2005;48(2):370-8. doi: 10.1007/s00125-004-1628-2. [PubMed: 16092810].
9. Astrup A, Tarnow I, Pietrassak L, Schalkwijk CG, Stehouwer CD, Parsley HH, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care. 2008;31(6):1170-6. doi: 10.2337/dc07-1960. [PubMed: 18312513].
10. Mizoguchi E. Chitinase 3-like1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology. 2006;130(2):398-411. doi: 10.1053/j.gastro.2005.12.007. [PubMed: 16472595].
11. Renkema GH, Root BG, Au FL, Donker-Koopman WE, Strijland A, Muisers AO, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251(2):504-9. [PubMed: 9492324].
12. Volck B, Price PA, Johansen JS, Sorensen O, Bengtli TF, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110(3):355-60. [PubMed: 9686683].
13. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res. 2006;55(2):53-9. doi: 10.1007/s00011-005-0010-8. [PubMed: 16612564].
14. Saba M, Sharif MR, Akbari H, Nikoueinejad H, Ramazani Jolfaii M. YKL-40 in Asthma and its correlation with different clinical parameters. Iran J Allergy Asthma Immunol. 2014;13(4):276-8. doi: 10.2337/2005.12.007. [PubMed: 16472595].
15. Peng C, Peng J, Jiang B, Qiu G, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38(3):444-57. doi: 10.1177/0308060X10038004027. [PubMed: 20926018].
16. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon L, Medina-Pestana JO, Lanzoni VP, Ferraz ML, et al. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. J Gastroenterol Hepatol. 2011;26(1):65-22. doi: 10.1111/j.1440-1746.2010.0637203. [PubMed: 20853827].
17. Canto E, Reverter F, Morcillo-Suarez C, Matesanz F, Fernandez O, Izquierdo G, et al. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler. 2012;18(7):983-90. doi: 10.1177/1352458510384061. [PubMed: 21893936].
18. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55(6):221-7. doi: 10.1007/s00011-006-0076-y. [PubMed: 16955240].
19. Rathcke CN, Persson F, Tarnow I, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32(2):323-8. doi: 10.2337/dc08-1444. [PubMed: 18957531].

Shiasi K et al.

Nephro-Urol Mon. 2017; 9(5):e12431.
20. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. *Int J Cardiol.* 2010;143(1):35–42. doi: 10.1016/j.ijcard.2009.01.043. [PubMed: 19223085].

21. Sakamoto F, Katakami N, Kaneto H, Yasuda T, Takahara M, Miyashita K, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. *Endocrinology.* 2011;60(1):73–9. [PubMed: 22986489].

22. Rondbjerg AK, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. *Cardiovasc Diabetol.* 2011;10:54. doi: 10.1186/1475-2840-10-54. [PubMed: 21696606].

23. Kyrgios I, Galli-Tsinopoulou A, Stylianou C, Papakonstantinou E, Arvanitidou M, Haidich AB. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. *Metabolism.* 2012;61(4):562–8. doi: 10.1016/j.metabol.2011.09.004. [PubMed: 22036069].

24. El-Mesallamy HO, Mostafa AM, Amin AI, El Demerdash E. The interplay of YKL-40 and leptin in type 2 diabetic obese patients. *Diabetes Res Clin Pract.* 2011;93(3):e113–6. doi: 10.1016/j.diabres.2011.05.040. [PubMed: 21715039].

25. Lee JH, Kim SS, Kim IJ, Song SH, Kim YK, In Kim J, et al. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. *Diabetes Res Complications.* 2012;26(4):562–8. doi: 10.1016/j.metabol.2011.09.004. [PubMed: 22036069].

26. El-Mesallamy HO, Mostafa AM, Amin AI, El Demerdash E. The interplay of YKL-40 and leptin in type 2 diabetic obese patients. *Diabetes Res Clin Pract.* 2011;93(3):et3–6. doi: 10.1016/j.diabres.2011.05.040. [PubMed: 21715039].

27. Lee [H, Kim SS, Kim H, Song SH, Kim YK, In Kim J, et al. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. *Diabetes Complications.* 2012;26(4):562–8. doi: 10.1016/j.metabol.2011.09.004. [PubMed: 22036069].

28. Persson F, Rathcke CN, Gall MA, Parving HH, Vestergaard H, Rossing P. High YKL-40 levels predict mortality in patients with type 2 diabetes. *Diabetes Res Clin Pract.* 2012;96(1):84–9. doi: 10.1016/j.diabres.2011.12.008. [PubMed: 22209020].

29. Brix JM, Holler F, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 in type 2 diabetic patients with different levels of albuminuria. *Eur J Clin Invest.* 2011;41(6):589–96. doi: 10.1111/j.1365-2362.2010.02446.x. [PubMed: 2158852].

29. Batinic K, Hobaus C, Grujicic M, Steffan A, Jelic F, Lorant D, et al. YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes. *Atherosclerosis.* 2012;222(2):557–63. doi: 10.1016/j.atherosclerosis.2012.03.014. [PubMed: 22572001].

30. Yasuda T, Katakami N, Kuroda A, Matsuoka T, Yamasaki Y, et al. YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. *Diabetes Res Clin Pract.* 2011;91(2):e50–2. doi: 10.1016/j.diabres.2010.11.015.

31. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. *Coronary Artery Dis.* 2007;18(5):391–6. doi: 10.1097/MCA.0b013e328241d991.

32. Fantino E, Gangell CI, Harrl D, Sly PD. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. *BMC Pulmonar Med.* 2014;14(1). doi: 10.1186/1471-2466-14-28.

33. Wang D, Lu J, Wang Q, Du X1, Dong R, Wang P, et al. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension. *Braz J Med Biol Res.* 2012;45(3):264–72. doi: 10.1590/S0100-879X2012000500010.

34. Jaksh P, Taghavi S, Klepetko W, Salama M. Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations independently predict bronchiolitis obliterans development in lung transplant recipients. *J Thorac Cardiovasc Surg.* 2014;148(1):273–81. doi: 10.1016/j.jtcvs.2014.02.059.

35. Schaller G, Brix JM, Placher-Sorgo K, Höller F, Schernthaner GH, Schernthaner G. YKL-40 concentrations are not elevated in gestational diabetes. *Eur J Clin Investig.* 2010;40(4):339–43. doi: 10.1111/j.1365-2362.2010.02274.x.